Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of survival and patterns of recurrence in a prospective, phase II single-arm trial.

Authors

Pooja Karukonda

Duke Cancer Institute, Durham, NC

Pooja Karukonda , Dominic LaBella , Brian G. Czito , Eileen Duffy , Hope Elizabeth Uronis , Thomas A. D'Amico , John H Strickler , Donna Niedzwiecki , Christopher Willett , Manisha Palta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.

First Author: Pooja Karukonda

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Radical radiotherapy for muscle-invasive bladder cancer: A single centre experience.

First Author: Mayumi Forster

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

First Author: Jared Cohen

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

First Author: Zhen Zeng